BLACK BOX WARNING
- premature discontinuation increases stroke risk in AF; epidural/spinal hematoma risk with neuraxial anesthesia or spinal puncture
edoxaban
Brand: Savaysa, Lixiana
⚠ BBW ISMP High Alert Prototype: rivaroxaban
Drug Class: direct oral anticoagulant (DOAC)
Drug Family: anticoagulant
Subclass: direct factor Xa inhibitor
Organ Systems: cardiovascularhematology-oncology
Mechanism of Action
Selectively inhibits free and clot-bound factor Xa, blocking the prothrombinase complex and preventing thrombin generation; does not require antithrombin as a cofactor, providing predictable anticoagulation without routine INR monitoring.
Factor Xa
Indications
- nonvalvular atrial fibrillation (stroke prevention)
- treatment of DVT and pulmonary embolism following 5-10 days of initial parenteral anticoagulation
Contraindications
- active pathological bleeding
- moderate to severe mitral stenosis
- mechanical heart valves
- CrCl >95 mL/min for AF indication (reduced efficacy)
- hypersensitivity
Adverse Effects
Common
- bleeding (minor)
- anemia
- rash
- abnormal liver function tests
Serious
- major bleeding (intracranial, GI, fatal)
- epidural/spinal hematoma with neuraxial anesthesia
Pharmacokinetics (ADME)
| Absorption | approximately 62% oral bioavailability; not significantly affected by food |
| Distribution | Vd approximately 107 L; 55% protein bound |
| Metabolism | minimal CYP3A4 (<4%); primarily hydrolysis and conjugation; P-gp substrate |
| Excretion | renal (50%) and fecal (50%); dose reduction required when CrCl 15-50 mL/min |
| Half-life | 10-14 hours |
| Onset | 1-2 hours |
| Peak | 1-2 hours |
| Duration | 24 hours |
| Protein Binding | 55% |
| Vd | approximately 107 L |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| rifampin | P-gp induction reduces edoxaban exposure by approximately 35%; avoid combination | major |
| P-gp inhibitors (dronedarone, quinidine) | increase edoxaban exposure; dose reduction to 30 mg recommended | major |
| NSAIDs/antiplatelet agents | additive bleeding risk | moderate |
Nursing Considerations
- For AF indication, edoxaban is contraindicated when CrCl exceeds 95 mL/min due to reduced stroke prevention efficacy; always verify renal function before initiating.
- Following parenteral anticoagulation for DVT/PE, transition to edoxaban after 5-10 days; do not initiate edoxaban simultaneously with parenteral therapy.
- Monitor for signs of bleeding including unexplained hemoglobin drops, hypotension, neurological changes, or unusual bruising; spinal/epidural hematoma symptoms (back pain, numbness) require emergency response.
- Edoxaban has no widely available antidote in routine clinical settings; andexanet alfa may be used for life-threatening bleeding but availability varies — notify prescriber immediately for serious bleeding events.
Clinical Pearls
- Edoxaban is unique among DOACs in that it is contraindicated for AF stroke prevention when CrCl exceeds 95 mL/min — higher renal clearance paradoxically lowers drug exposure below therapeutic levels.
- The requirement for 5-10 days of initial parenteral anticoagulation before transitioning to edoxaban for VTE treatment distinguishes its dosing sequence from rivaroxaban and apixaban, which can be started directly.
Safety Profile
Pregnancy avoid
Lactation insufficient-data
Renal Adjustment Required
Hepatic Adjustment Required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.